Trials / Completed
CompletedNCT02280421
Drug-Drug Interaction Study: ASP2151 and Ciclosporin
A Single-centre, Open-label, Randomised, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Repeated Oral Doses of Ciclosporin on the Single-dose Pharmacokinetics of nASP2151 in Healthy Mean
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Maruho Europe Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
ASP2151 is an experimental treatment for herpes. Patients undergoing organ and tissue transplantation may be prescribed ciclosporin to suppress their immune system to give the transplant an increased chance of not being rejected. A patient with a compromised immune system is more susceptible to infections such as herpes, which will require treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP2151 400mg + 100mg ciclosporin | |
| DRUG | ASP2151 1200mg + 100mg ciclosporin |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2014-10-31
- Last updated
- 2019-05-03
- Results posted
- 2019-05-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02280421. Inclusion in this directory is not an endorsement.